Flag of the European Union EU Clinical Trials Register Help

Clinical trials

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   43845   clinical trials with a EudraCT protocol, of which   7282   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     

    < Back to search results

    Print Download

    Summary
    EudraCT Number:2017-001042-10
    Sponsor's Protocol Code Number:VX16-150-102
    National Competent Authority:Italy - Italian Medicines Agency
    Clinical Trial Type:EEA CTA
    Trial Status:Completed
    Date on which this record was first entered in the EudraCT database:2021-01-07
    Trial results View results
    Index
    A. PROTOCOL INFORMATION
    B. SPONSOR INFORMATION
    C. APPLICANT IDENTIFICATION
    D. IMP IDENTIFICATION
    D.8 INFORMATION ON PLACEBO
    E. GENERAL INFORMATION ON THE TRIAL
    F. POPULATION OF TRIAL SUBJECTS
    G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL
    N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED
    P. END OF TRIAL
    Expand All   Collapse All
    A. Protocol Information
    A.1Member State ConcernedItaly - Italian Medicines Agency
    A.2EudraCT number2017-001042-10
    A.3Full title of the trial
    A Phase 2, Randomized, Double-blind, Placebo-controlled, 6-Week, Parallel-design Study of the Efficacy and Safety of VX-150 in Treating Subjects With Pain Caused by Small Fiber Neuropathy
    Uno studio in parallelo di fase 2, randomizzato, in doppio cieco, controllato con placebo, di 6 settimane, sull¿efficacia e la sicurezza di VX-150 nel trattamento di soggetti affetti da dolore causato da neuropatia delle piccole fibre
    A.3.1Title of the trial for lay people, in easily understood, i.e. non-technical, language
    A study to investigate how safe and able to produce an effect in the body study drug VX-150 is in patients with pain that typically begins in the feet or hand
    Studio per indagare quanto VX-150 sia sicuro e capace di produrre un effetto sull'organismo in pazienti con dolore che tipicamente inizia ai piedi ad alla mano.
    A.3.2Name or abbreviated title of the trial where available
    NA
    NA
    A.4.1Sponsor's protocol code numberVX16-150-102
    A.7Trial is part of a Paediatric Investigation Plan No
    A.8EMA Decision number of Paediatric Investigation Plan
    B. Sponsor Information
    B.Sponsor: 1
    B.1.1Name of SponsorVERTEX PHARMACEUTICALS INCORPORATED
    B.1.3.4CountryUnited States
    B.3.1 and B.3.2Status of the sponsorCommercial
    B.4 Source(s) of Monetary or Material Support for the clinical trial:
    B.4.1Name of organisation providing supportVERTEX PHARMACEUTICALS INCORPORATED
    B.4.2CountryUnited States
    B.5 Contact point designated by the sponsor for further information on the trial
    B.5.1Name of organisationVERTEX PHARMACEUTICALS INCORPORATED
    B.5.2Functional name of contact pointClinical Trials and Medical Info
    B.5.3 Address:
    B.5.3.1Street Address50 Northern Avenue
    B.5.3.2Town/ cityBoston, Massachusetts
    B.5.3.3Post code02210
    B.5.3.4CountryUnited States
    B.5.4Telephone number+1 877 634-8789
    B.5.5Fax number+1 510 595-8183
    B.5.6E-mailmedicalinfo@vrtx.com
    D. IMP Identification
    D.IMP: 1
    D.1.2 and D.1.3IMP RoleTest
    D.2 Status of the IMP to be used in the clinical trial
    D.2.1IMP to be used in the trial has a marketing authorisation No
    D.2.5The IMP has been designated in this indication as an orphan drug in the Community No
    D.2.5.1Orphan drug designation number
    D.3 Description of the IMP
    D.3.1Product nameVX-150
    D.3.2Product code VX-150
    D.3.4Pharmaceutical form Capsule, hard
    D.3.4.1Specific paediatric formulation No
    D.3.7Routes of administration for this IMPOral use
    D.3.8 to D.3.10 IMP Identification Details (Active Substances)
    D.3.9.2Current sponsor codeVX-150
    D.3.9.4EV Substance CodeSUB181412
    D.3.10 Strength
    D.3.10.1Concentration unit mg milligram(s)
    D.3.10.2Concentration typeequal
    D.3.10.3Concentration number250
    D.3.11 The IMP contains an:
    D.3.11.1Active substance of chemical origin Yes
    D.3.11.2Active substance of biological/ biotechnological origin (other than Advanced Therapy IMP (ATIMP) No
    The IMP is a:
    D.3.11.3Advanced Therapy IMP (ATIMP) No
    D.3.11.3.1Somatic cell therapy medicinal product Information not present in EudraCT
    D.3.11.3.2Gene therapy medical product Information not present in EudraCT
    D.3.11.3.3Tissue Engineered Product Information not present in EudraCT
    D.3.11.3.4Combination ATIMP (i.e. one involving a medical device) Information not present in EudraCT
    D.3.11.3.5Committee on Advanced therapies (CAT) has issued a classification for this product Information not present in EudraCT
    D.3.11.4Combination product that includes a device, but does not involve an Advanced Therapy No
    D.3.11.5Radiopharmaceutical medicinal product No
    D.3.11.6Immunological medicinal product (such as vaccine, allergen, immune serum) No
    D.3.11.7Plasma derived medicinal product No
    D.3.11.8Extractive medicinal product No
    D.3.11.9Recombinant medicinal product No
    D.3.11.10Medicinal product containing genetically modified organisms No
    D.3.11.11Herbal medicinal product No
    D.3.11.12Homeopathic medicinal product No
    D.3.11.13Another type of medicinal product No
    D.8 Information on Placebo
    D.8 Placebo: 1
    D.8.1Is a Placebo used in this Trial?Yes
    D.8.3Pharmaceutical form of the placeboCapsule, hard
    D.8.4Route of administration of the placeboOral use
    E. General Information on the Trial
    E.1 Medical condition or disease under investigation
    E.1.1Medical condition(s) being investigated
    Pain Caused by Small Fiber Neuropathy
    Dolore causato da neuropatia delle piccole fibre
    E.1.1.1Medical condition in easily understood language
    Severe pain attacks that typically begin in the feet or hands
    Attacchi di forte dolore che solitamente hanno inizio ai piedi o alle mani
    E.1.1.2Therapeutic area Body processes [G] - Bones and nerves physological processes [G11]
    MedDRA Classification
    E.1.2 Medical condition or disease under investigation
    E.1.2Version 20.0
    E.1.2Level PT
    E.1.2Classification code 10033371
    E.1.2Term Pain
    E.1.2System Organ Class 10018065 - General disorders and administration site conditions
    E.1.2 Medical condition or disease under investigation
    E.1.2Version 20.1
    E.1.2Level PT
    E.1.2Classification code 10073928
    E.1.2Term Small fibre neuropathy
    E.1.2System Organ Class 10029205 - Nervous system disorders
    E.1.3Condition being studied is a rare disease No
    E.2 Objective of the trial
    E.2.1Main objective of the trial
    To evaluate the efficacy of VX-150 for the treatment of pain caused by small fiber neuropathy
    Valutare l¿efficacia di VX-150 per il trattamento del dolore causato da neuropatia delle piccole fibre
    E.2.2Secondary objectives of the trial
    ¿ To evaluate the safety and tolerability of VX-150
    ¿ To evaluate the PK of VRT-1207355 and the metabolite VRT-1268114
    ¿ Valutare la sicurezza e la tollerabilit¿ di VX-150
    ¿ Valutare la farmacocinetica (PK) di VRT-1207355 e del metabolita VRT-1268114
    E.2.3Trial contains a sub-study No
    E.3Principal inclusion criteria
    1. Subject will sign and date an informed consent form (ICF)
    2. Willing and able to comply with scheduled visits, treatment plan, study restrictions, laboratory tests, contraceptive guidelines, and other study procedures
    3. Subjects (male and female) will be between the ages of 18 and 80 years, inclusive.
    4. Body mass index (BMI) = 18.0
    5. Diagnosis of small fiber neuropathy, as per European Federation Neurological Societies (EFNS)/American Academy of Neurology (AAN)
    guidelines, with pain for at least 3 months prior to screening
    6. Reduction below the 5th percentile of sex and age-adjusted normal values in epidermal nerve fiber density on punch skin biopsy at the distal site of the leg performed at or within 6 months of screening
    7. Presence of sural nerve response
    8. Average NRS score between =4 and =9 reported in the daily diary on Days -7 through -1
    1. Il soggetto firmerà e apporrà la data sul modulo di consenso informato (ICF)
    2. Disponibilità e capacità di rispettare le visite programmate, il piano di trattamento, le restrizioni previste dallo studio, sottoporsi agli esami di laboratorio, attenersi alle linee guida relative alle misure contraccettive e alle altre procedure dello studio
    3. I soggetti (uomini e donne) dovranno avere un’età compresa tra 18 e 80 anni inclusi.
    4. Indice di massa corporea (IMC) =18,0 kg/m2
    5. Diagnosi di neuropatia delle piccole fibre, secondo le linee guida della European Federation Neurological Societies (EFNS)/American Academy of Neurology (AAN) sul ruolo della biopsia cutanea nella diagnosi della neuropatia delle piccole fibre, con dolore per almeno 3 mesi prima dello screening e con segni clinici di disturbi legati alla percezione termica o del dolore compatibili con una distribuzione periferica della neuropatia all'esame neurologico (ad es. con distribuzione a guanto e calza)
    6. Riduzione al di sotto del 5° percentile del valori normali corretti per il sesso per la densità di fibra nervosa dell’epidermide in una biopsia cutanea con punzone eseguita allo screening o entro 6 mesi da esso nel sito distale della gamba
    7. Presenza di risposta del nervo surale
    8. Punteggio NRS medio da =4 a =9 registrato nel diario giornaliero dal Giorno -7 al Giorno -1
    E.4Principal exclusion criteria
    1. History in the past 10 years of malignancy except for squamous cell skin cancer, basal cell skin cancer, and Stage 0 cervical carcinoma in situ (all 3 with no recurrence for the last 5 years)
    2. Exposure to neurotoxic drugs (i.e., chemotherapy) since diagnosis of small fiber neuropathy. Untreated or uncontrolled connective tissue disorders, sarcoidosis, Sjögren's syndrome, amyloidosis, Fabry's disease, celiac disease, Lyme disease, autoimmune disorders (i.e., as assessed by anti-nuclear antibodies, rheumatoid factor, sedimentation rate, and/or lupus anti-coagulant) including myasthenia gravis and Guillain-Barre syndrome, which in the opinion of the investigator makes the subject unsuitable for inclusion in this study.
    3. A known or clinically suspected infection with human immunodeficiency virus or hepatitis B or C viruses
    4. Current clinically significant liver or kidney dysfunction
    5. Current uncontrolled thyroid dysfunction
    6. Subjects with a diagnosis of diabetes who have any 1 of the following criteria:
    • HbA1c = 11% at screening
    • are not stabilized on oral hypoglycemics and/or subcutaneous insulin or diet, in the opinion of the investigator
    • evidence of ulcers or severe nephropathy resulting from their diabetes
    • advanced retinopathy, defined as greater than State 3 (moderate nonproliferative diabetic retinopathy)15
    • history of a clinical atherosclerotic event, such as myocardial infarction or stroke
    7. History of cardiac dysrhythmias requiring anti-arrhythmia treatment(s); or history or evidence of abnormal ECGs that in the opinion of the investigator or medical monitor would preclude the subject's participation in the study
    8. Standard 12-lead ECG demonstrating QTc >450 msec at screening. If QTc exceeds 450 msec, the ECG will be repeated 2 more times, and the average of the 3 QTc values will be used to determine the subject's eligibility.
    9. Concomitant severe pain conditions (i.e., low back pain, radiculopathy, severe bone and musculoskeletal disorders) which may impair self-assessment of pain due to small fiber neuropathy
    10. Abnormal laboratory results indicative of any significant medical disease that, in the opinion of the investigator, would preclude the subject's participation in the study
    11. Other serious, acute, or chronic medical or psychiatric illness that, in the judgment of the investigator, could compromise subject safety, limit
    the subject's ability to complete the study and/or compromise the objectives of the study
    12. Female subjects who are pregnant, nursing, or planning to become pregnant during the study or within 90 days after the last study drug dose
    13. Male subjects with a female partner who is pregnant, nursing, or planning to become pregnant during the study or within 90 days after the last study drug dose
    14. Use of restricted medication or food within the specified duration before the first dose of study drug
    15. Alcohol, analgesic/opioid, and/or illicit drug abuse as defined by the American Psychiatric Association Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition, in the last 12 months before screening, or a positive test for drugs of abuse at screening
    • A positive drug screen for a known concomitant medication that is not otherwise exclusionary (e.g., benzodiazepines) will not disqualify subjects; however, marijuana and marijuana derivatives will not be allowed
    16. Subject, or close relative of the subject, is the investigator or a subinvestigator, research assistant, pharmacist, study coordinator, or other staff directly involved with the conduct of the study at that site
    1. Anamnesi di neoplasia maligna negli ultimi anni, eccetto tumore della pelle a cellule squamose, tumore della pelle a cellule basali e carcinoma della cervice in situ Stadio 0 (tutti e 3 in assenza di recidive negli ultimi 5 anni)
    2. Esposizione a farmaci neurotossici (ovvero chemioterapia) dalla diagnosi di neuropatia delle piccole fibre. Disturbi non trattati o non controllati del tessuto connettivo, sarcoidosi, sindrome di Sjögren, amiloidosi, malattia di Fabry, celiachia, malattia di Lyme, disturbi autoimmuni (ovvero, come da valutazione con anticorpi antinucleari, fattore reumatoide, velocità di sedimentazione e/o lupus anticoagulante) compresi miastenia grave e sindrome di Guillain-Barre che, secondo il parere dello sperimentatore, rendono il soggetto inadatto per l’inclusione in questo studio.
    3. Nota o sospetta infezione clinica da virus dell’immunodeficienza o dell’epatite B o dell’epatite C
    4. Disfunzione attuale clinicamente significativa epatica o renale
    5. Disfunzione attuale non controllata della tiroide
    6. Soggetti con diagnosi di diabete che presentano uno qualsiasi dei seguenti criteri:
    ¿ HbA1c =11% allo screening.
    ¿ non trattati con una terapia stabile a base di ipoglicemici orali e/o insulina sottocutanea o un regime alimentare adeguato secondo il parere dello sperimentatore
    ¿ evidenza di ulcere o nefropatia grave di origine diabetica
    ¿ retinopatia avanzata, ovvero di grado superiore a 3 (retinopatia diabetica moderata non proliferativa)15
    ¿ anamnesi di evento aterosclerotico clinico, quale infarto miocardico o ictus
    7. Anamnesi di disritmie cardiache che richiedono trattamenti anti-aritmia oppure anamnesi o evidenza di anomalie ECG che, secondo il parere dello sperimentatore o del monitoraggio medico, impedirebbero la partecipazione allo studio del soggetto
    8. ECG standard a 12 derivazioni dimostrativo di intervallo QTc >450 msec allo screening. Se l’intervallo QTc è maggiore di 450 msec, l’ECG verrà ripetuto altre 2 volte e verrà utilizzata la media dei 3 valori per stabilire l’idoneità del soggetto.
    9. Condizioni concomitanti di dolore grave (ovvero dolore alla porzione lombare della schiena, radicolopatia, gravi disturbi ossei e muscoloscheletrici) che possono influenzare l’autovalutazione del dolore dovuto alla neuropatia da piccole fibre
    10. Anomalie nei risultati di laboratorio che indicano una patologia medica significativa che, secondo il parere dello sperimentatore, impedirebbero la partecipazione allo studio del soggetto
    11. Altra malattia grave, acuta o cronica, di natura medica o psichiatrica, che, secondo il parere dello sperimentatore, potrebbe compromettere la sicurezza del soggetto, limitarne la capacità di completare lo studio e/o compromettere gli obiettivi dello studio
    12. Soggetti di sesso femminile in gravidanza, in allattamento al seno o che prevedono di entrare in gravidanza durante lo studio o entro 90 giorni dall'assunzione dell'ultima dose di farmaco in studio
    13. Soggetti di sesso maschile con partner donna in gravidanza, in allattamento al seno o che prevede una gravidanza/entra in gravidanza durante lo studio o entro 90 giorni dall’assunzione dell’ultima dose di farmaco in studio
    14. Utilizzo di farmaci o cibi limitati entro il periodo specificato prima della prima dose del farmaco in studio, come definito nella Tabella 9-1
    15. Abuso di alcool, analgesici/oppioidi e/o droghe illegali come definito dal Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition dell’American Psychiatric Association, negli ultimi 12 mesi prima dello screening o test positivo per le droghe d’abuso allo screening
    • Una risultanza positiva per una droga che risulta essere un farmaco concomitante noto non diversamente esclusivo (ad es. le benzodiazepine) non determina l’esclusione del soggetto; tuttavia la marijuana e i suoi derivati non sono ammessi
    16. Il soggetto o un parente stretto del soggetto è lo sperimentatore o uno sperimentatore secondario, un assistente alla ricerca, il farmacista, il coordinatore dello studio o altro personale direttamente coinvolto nella conduzione dello studio presso il centro.
    E.5 End points
    E.5.1Primary end point(s)
    Change from baseline in the weekly average of daily pain intensity on the 11-point numeric rating scale (NRS), as reported in the daily diary, at Week 6
    Variazione dal basale nella media settimanale dell’intensità del dolore giornaliero su una scala di valutazione numerica (NRS) a 11 punti, come riportato nel diario giornaliero, alla Settimana 6
    E.5.1.1Timepoint(s) of evaluation of this end point
    Week 6
    Settimana 6
    E.5.2Secondary end point(s)
    ¿ Proportion of subjects with =30% reduction in the weekly average of daily pain intensity on the 11- point NRS, as reported in the daily diary, at Week 6
    ¿ Proportion of subjects with =50% reduction in the weekly average of daily pain intensity on the 11-point NRS, as reported in the daily diary, at Week 6
    ¿ Change from baseline in the Daily Sleep Interference Scale (DSIS) at Week 6
    ¿ Proportion of subjects categorized as improved at Week 6 on the patient global impression of change (PGIC) assessment
    ¿ Change from baseline in pain intensity on the 11-point NRS, as reported at study visits, at Week 6
    ¿ Plasma PK parameters of VRT-1207355 and the metabolite VRT-1268114
    ¿ Safety and tolerability based on the Columbia Suicide Severity Rating Scale (C-SSRS), incidence and type of AEs, changes from baseline in clinically significant laboratory test results, vital signs, and ECGs at each visit
    ¿ Percentuale di soggetti con una riduzione =30% nella media settimanale dell¿intensit¿ del dolore giornaliero sulla scala NRS a 11 punti, come riportato nel diario giornaliero, alla Settimana 6
    ¿ Percentuale di soggetti con una riduzione =50% nella media settimanale dell¿intensit¿ del dolore giornaliero sulla scala NRS a 11 punti, come riportato nel diario giornaliero, alla Settimana 6
    ¿ Variazione dal basale sulla scala dell¿interferenza sul sonno giornaliero (DSIS) alla Settimana 6
    ¿ Percentuale di soggetti classificati come migliorati alla Settimana 6 nella valutazione dell¿impressione globale di cambiamento del paziente (PGIC)
    ¿ Variazione dal basale nell¿intensit¿ del dolore sulla scala NRS a 11 punti, come riportato nelle visite dello studio, alla Settimana 6
    ¿ Parametri di PK plasmatica di VRT-1207355 e del metabolita VRT-1268114
    ¿ Sicurezza e tollerabilit¿ basate sulla Columbia Suicide Severity Rating Scale (C-SSRS), incidenza e tipo di eventi avversi (EA), variazioni dal basale in risultati di test di laboratorio clinicamente significativi, segni vitali ed ECG a ogni visita
    E.5.2.1Timepoint(s) of evaluation of this end point
    ¿ At week 6
    ¿ Plasma PK parameters at day 7, week 3, week 6 and early termination visit
    ¿ Safety and tolerability at each visit
    ¿ Alla Settimana 6
    ¿ parametri di PK plasmatica al Giorno 7, alla Settimana 3, alla Settimana 6 e alla Visita di interruzione anticipata del trattamento
    ¿ Sicurezza e tollerabilit¿ ad ogni visita
    E.6 and E.7 Scope of the trial
    E.6Scope of the trial
    E.6.1Diagnosis No
    E.6.2Prophylaxis No
    E.6.3Therapy No
    E.6.4Safety Yes
    E.6.5Efficacy Yes
    E.6.6Pharmacokinetic Yes
    E.6.7Pharmacodynamic No
    E.6.8Bioequivalence No
    E.6.9Dose response No
    E.6.10Pharmacogenetic No
    E.6.11Pharmacogenomic No
    E.6.12Pharmacoeconomic No
    E.6.13Others Yes
    E.6.13.1Other scope of the trial description
    Tolerability
    Tollerabilit¿
    E.7Trial type and phase
    E.7.1Human pharmacology (Phase I) No
    E.7.1.1First administration to humans No
    E.7.1.2Bioequivalence study No
    E.7.1.3Other No
    E.7.1.3.1Other trial type description
    E.7.2Therapeutic exploratory (Phase II) Yes
    E.7.3Therapeutic confirmatory (Phase III) No
    E.7.4Therapeutic use (Phase IV) No
    E.8 Design of the trial
    E.8.1Controlled Yes
    E.8.1.1Randomised Yes
    E.8.1.2Open No
    E.8.1.3Single blind No
    E.8.1.4Double blind Yes
    E.8.1.5Parallel group Yes
    E.8.1.6Cross over No
    E.8.1.7Other No
    E.8.2 Comparator of controlled trial
    E.8.2.1Other medicinal product(s) No
    E.8.2.2Placebo Yes
    E.8.2.3Other No
    E.8.2.4Number of treatment arms in the trial2
    E.8.3 The trial involves single site in the Member State concerned Yes
    E.8.4 The trial involves multiple sites in the Member State concerned No
    E.8.4.1Number of sites anticipated in Member State concerned1
    E.8.5The trial involves multiple Member States Yes
    E.8.5.1Number of sites anticipated in the EEA4
    E.8.6 Trial involving sites outside the EEA
    E.8.6.1Trial being conducted both within and outside the EEA Yes
    E.8.6.2Trial being conducted completely outside of the EEA Information not present in EudraCT
    E.8.6.3If E.8.6.1 or E.8.6.2 are Yes, specify the regions in which trial sites are planned
    Canada
    United States
    Germany
    Italy
    Netherlands
    E.8.7Trial has a data monitoring committee No
    E.8.8 Definition of the end of the trial and justification where it is not the last visit of the last subject undergoing the trial
    LVLS
    LVLS
    E.8.9 Initial estimate of the duration of the trial
    E.8.9.1In the Member State concerned years0
    E.8.9.1In the Member State concerned months7
    E.8.9.1In the Member State concerned days0
    E.8.9.2In all countries concerned by the trial years0
    E.8.9.2In all countries concerned by the trial months7
    E.8.9.2In all countries concerned by the trial days0
    F. Population of Trial Subjects
    F.1 Age Range
    F.1.1Trial has subjects under 18 No
    F.1.1.1In Utero No
    F.1.1.2Preterm newborn infants (up to gestational age < 37 weeks) No
    F.1.1.3Newborns (0-27 days) No
    F.1.1.4Infants and toddlers (28 days-23 months) No
    F.1.1.5Children (2-11years) No
    F.1.1.6Adolescents (12-17 years) No
    F.1.2Adults (18-64 years) Yes
    F.1.2.1Number of subjects for this age range: 86
    F.1.3Elderly (>=65 years) Yes
    F.1.3.1Number of subjects for this age range: 28
    F.2 Gender
    F.2.1Female Yes
    F.2.2Male Yes
    F.3 Group of trial subjects
    F.3.1Healthy volunteers No
    F.3.2Patients Yes
    F.3.3Specific vulnerable populations No
    F.3.3.1Women of childbearing potential not using contraception No
    F.3.3.2Women of child-bearing potential using contraception No
    F.3.3.3Pregnant women No
    F.3.3.4Nursing women No
    F.3.3.5Emergency situation No
    F.3.3.6Subjects incapable of giving consent personally No
    F.3.3.7Others No
    F.4 Planned number of subjects to be included
    F.4.1In the member state60
    F.4.2 For a multinational trial
    F.4.2.1In the EEA 72
    F.4.2.2In the whole clinical trial 114
    F.5 Plans for treatment or care after the subject has ended the participation in the trial (if it is different from the expected normal treatment of that condition)
    Standard of care
    Standard of care
    G. Investigator Networks to be involved in the Trial
    N. Review by the Competent Authority or Ethics Committee in the country concerned
    N.Competent Authority Decision Authorised
    N.Date of Competent Authority Decision2017-11-08
    N.Ethics Committee Opinion of the trial applicationFavourable
    N.Ethics Committee Opinion: Reason(s) for unfavourable opinion
    N.Date of Ethics Committee Opinion2017-07-12
    P. End of Trial
    P.End of Trial StatusCompleted
    P.Date of the global end of the trial2018-11-08
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Fri Apr 19 08:30:09 CEST 2024 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA